NCT04895735View on ClinicalTrials.gov

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

August 13, 2025

Study Completion Date

February 28, 2028

Conditions
Metastatic Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage IV Major Salivary Gland Cancer AJCC v8Adenoid Cystic Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Pemetrexed Disodium

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

PSMA PET Scan

Undergo PSMA PET

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04895735 - MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | Biotech Hunter | Biotech Hunter